IB Times -- The US New Drug Application for asthma drug Flutiform is being transferred to SkyePharma. Last month the US Food and Drug Administration rebuffed the NDA and said there were “substantive” issues that needed to be resolved ahead of an approval. SkyePharma believes the transfer of the NDA will enable it to deal directly with the FDA in these discussions.
